Tier 4 — mechanistic

Endogenous and exogenous mediators of quercetin bioavailability

Yi Guo, Richard S Bruno
The Journal of nutritional biochemistry 2015 26(3):201

Bibliography

PubMed
PMID 25468612
DOI
10.1016/j.jnutbio.2014.10.008
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignNarrative review of pharmacokinetics and bioavailability determinants
ModelNarrative or mixed evidence review
SampleClinical and animal absorption studies; no new trial cohort
InterventionQuercetin forms, food matrices, host factors, and delivery systems
DurationLiterature available at publication
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2015, this source examined forms, absorption and food sources. Its evidence base was Clinical and animal absorption studies; no new trial cohort. It evaluated Quercetin forms, food matrices, host factors, and delivery systems across Literature available at publication.

The review describes low and variable exposure and strategies that might improve it.

Whether increased exposure improves clinical cardiovascular outcomes remained unresolved. Animal absorption strategies and metabolite effects cannot be assumed to transfer directly to people.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The review describes low and variable exposure and strategies that might improve it.
  • The recorded outcome domains were Exposure and pharmacokinetics.

What this study can and cannot tell us

  • Whether increased exposure improves clinical cardiovascular outcomes remained unresolved. Animal absorption strategies and metabolite effects cannot be assumed to transfer directly to people.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 4
A critical examination of human data for the biological activity of quercetin and its phase-2 conjugates
Gary Williamson et al. · Critical reviews in food science and nutrition · 2025
Tier 4
Enzymatically Modified Isoquercitrin: Production, Metabolism, Bioavailability, Toxicity, Pharmacology, and Related Molecular Mechanisms
Aleksandra Owczarek-Januszkiewicz et al. · International journal of molecular sciences · 2022
Tier 4
Recent advances on the improvement of quercetin bioavailability
Kevser Kandemir et al. · Trends in Food Science & Technology · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology